Compare PIM & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIM | SGHT |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 187.4M |
| IPO Year | N/A | 2021 |
| Metric | PIM | SGHT |
|---|---|---|
| Price | $3.30 | $3.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.08 |
| AVG Volume (30 Days) | 149.8K | ★ 296.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | $66.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.14 | $2.03 |
| 52 Week High | $3.50 | $9.24 |
| Indicator | PIM | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 36.94 |
| Support Level | $3.28 | $3.29 |
| Resistance Level | $3.38 | $3.76 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 79.22 | 22.14 |
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.